Abstract
BackgroundTargeting immunosuppressive checkpoints has proven to be an efficacious treatment strategy for non-small cell lung cancer (NSCLC), in which response rates are as high as 35% in patients harboring Kras/p53...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have